Nausicaa Ventures
Founded in 2009, Nausicaa Ventures is a Belgium-based venture capital firm specializing in early-stage and growth investments. It focuses on companies completing Series C or D financing rounds across various sectors such as healthcare technologies, ICT, manufacturing, clean tech, biotech, and industrial processes within a radius of 300 km from Brussels. The firm typically invests between €1 million to €4 million per company, with an average holding period of five years.
Top Stages
5 past transactions
Ngdata
Series C in 2017
NGDATA, headquartered in Ghent, Belgium, specializes in consumer intelligence management solutions. The company offers a customer data platform that integrates big data management and machine learning technologies, providing real-time insights and enabling personalized customer experiences. NGDATA serves various industries, including finance, retail, and media, with offices in Belgium, France, Singapore, and the United States.
Ngdata
Series B in 2017
NGDATA, headquartered in Ghent, Belgium, specializes in consumer intelligence management solutions. The company offers a customer data platform that integrates big data management and machine learning technologies, providing real-time insights and enabling personalized customer experiences. NGDATA serves various industries, including finance, retail, and media, with offices in Belgium, France, Singapore, and the United States.
Ovizio
Venture Round in 2015
Ovizio develops digital holographic interferometric microscopy products. It specializes in creating four-dimensional microscopic imaging devices and software based on digital holographic microscopy for life sciences research and bioprocessing.
Ngdata
Series B in 2015
NGDATA, headquartered in Ghent, Belgium, specializes in consumer intelligence management solutions. The company offers a customer data platform that integrates big data management and machine learning technologies, providing real-time insights and enabling personalized customer experiences. NGDATA serves various industries, including finance, retail, and media, with offices in Belgium, France, Singapore, and the United States.
Bone Therapeutics
Series D in 2013
Bone Therapeutics, a Belgian biotechnology company established in 2006, specializes in developing innovative cell therapy products to treat orthopedic conditions and bone diseases. Its flagship product, ALLOB, is an allogeneic cell therapy currently in Phase II trials for delayed-union fractures and spinal fusion.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.